True
For individuals who cannot tolerate the recommended high or moderate intensity statin, the maximum tolerated statin dose should be used. This is a consistent, explicit recommendation across all major cardiovascular guidelines.
Guideline Consensus
Multiple authoritative guidelines uniformly support using the maximum tolerated statin dose when standard intensity therapy cannot be tolerated:
The American Diabetes Association (2025,2024,2023) explicitly states: "For individuals who do not tolerate the intended intensity of statin, the maximum tolerated statin dose should be used" 1.
The ACC/AHA Cholesterol Guidelines (2014) recommend: "For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity" 1.
This applies across all risk categories, including patients with LDL-C ≥190 mg/dL, diabetes, and established ASCVD 1.
Clinical Rationale
The evidence supporting this approach is compelling:
Dose-dependent cardiovascular benefit: Meta-analyses demonstrate a 9% reduction in all-cause mortality and 13% reduction in vascular mortality for each 39 mg/dL reduction in LDL cholesterol, with benefits linearly related to LDL reduction without a lower threshold 1.
Any statin is better than no statin: Even low-dose statin therapy, while generally not recommended as first-line, may be the only tolerable option for some patients and still provides cardiovascular benefit 1.
Practical Management Strategy
When patients cannot tolerate intended statin intensity 2:
Try multiple statins: At least two different statins should be attempted, including one at the lowest approved daily dosage, before declaring true statin intolerance 3.
Dose modification strategies: Consider alternate-day dosing, very low doses gradually titrated upward, or switching to different statin molecules 2, 4.
Add non-statin therapy if needed: For high-risk patients not achieving goals on maximum tolerated statin, add ezetimibe or consider PCSK9 inhibitors 1, 2.
Important Caveats
Rule out nocebo effect: Many patients with perceived statin intolerance can actually tolerate therapy when rechallenged, as symptoms may be unrelated to the medication 3, 4.
Don't abandon lipid lowering: In high and very high-risk patients who are truly statin intolerant, initiate non-statin therapy while continuing attempts to identify a tolerable statin regimen to minimize time with elevated atherogenic lipoproteins 3.
Monitor response: Assess LDL-C 4-12 weeks after initiating or changing therapy to evaluate response and medication adherence 2.